What is Postherpetic Neuralgia?
Postherpetic neuralgia (PHN) is a chronic neuropathic pain condition characterized by severe pain that persists for 3 months or more after the herpes zoster (shingles) rash has resolved. 1, 2, 3
Pathophysiology and Mechanism
- PHN develops from reactivation of the varicella zoster virus, which remains dormant in the dorsal root ganglia or sensory ganglia of cranial nerves after primary varicella (chickenpox) infection 4
- When the virus reactivates, it travels along nerve pathways causing inflammation and direct damage to peripheral and central neurons, resulting in the characteristic painful rash with dermatomal distribution 4, 5
- The nerve damage leading to PHN may be a byproduct of the immune/inflammatory response accompanying varicella zoster virus reactivation 5
- The pathophysiology may differ distinctly between patients with either reduced or increased skin sensitivity 6
Clinical Presentation
Patients experience multiple types of pain including:
The pain follows a dermatomal distribution corresponding to the original shingles rash location 4
Pain can persist from months to years after the rash has completely healed 1, 2, 3
Epidemiology and Risk Factors
- PHN is the most common complication of herpes zoster, affecting approximately 1 million cases annually in the US 5
- At least half of shingles sufferers over age 65 develop PHN 2
- PHN accounts for 11-15% of all referrals to pain clinics 2
- The primary risk factors in order of importance are:
Impact on Quality of Life
- PHN can have a severe impact on patients' quality of life and functional ability 8
- Patients report decreased quality of life and significant interference with activities of daily living 5
- The condition can be incapacitating, particularly in patients with advanced disease and immunocompromised states 4
Common Pitfalls
- Do not confuse acute herpes zoster pain with PHN - by definition, PHN only refers to pain persisting at least 3 months after the onset of the acute rash 2, 3
- PHN remains highly resistant to current treatments, requiring aggressive early management 8
- The condition is likely to increase in incidence due to greater longevity and increasing numbers of immunocompromised patients 6